With nearly 50 years of experience and expertise in the pharmaceutical and biopharmaceutical industry, we are focused on unique products, solutions and platforms for diagnostics, therapeutic and health care across Asia and emerging markets.

Innogene is actively involved in the acquisition, development and commercialization of products, one of the most prominent being TheraCIM, a monoclonal antibody for targeted cancer therapy.

TheraCIM has entered Phase III clinical trials, carried out since 2010 in collaboration with the National Cancer Center of Singapore (NCCS).

TheraCIM has obtained registration and has been marketed since the year 2008 in Indonesia, Philippines, Cambodia and Thailand.

In addition, TheraCIM is used through Name Patient basis in Taiwan, Singapore, and Malaysia; and the drug is allowed to be imported on a case by case basis.

Aside from TheraCIM, Innogene is currently developing Racotumomab, which is the first anti-idiotype cancer vaccine product in the world.

In 2011, research activities have started in several hospitals, including RS Dharmais in Indonesia, John Hopkins Hospital in Singapore and Veterans Hospital in the Philippines. Through Innogene, Kalbe is also planning to develop a number of biosimilar products, in collaboration with internationally-recognized research and development companies.